HC Wainwright Lowers REGENXBIO (NASDAQ:RGNX) Price Target to $36.00

REGENXBIO (NASDAQ:RGNX) had its price target reduced by HC Wainwright from $40.00 to $36.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the stock. Barclays dropped their price objective on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Raymond James reissued an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Chardan Capital reissued a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX opened at $9.59 on Thursday. The company has a market cap of $475.09 million, a P/E ratio of -1.91 and a beta of 1.23. The firm’s fifty day moving average is $10.24 and its two-hundred day moving average is $12.07. REGENXBIO has a 52-week low of $8.53 and a 52-week high of $28.80.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $114,101.46. The trade was a 46.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. FMR LLC boosted its position in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the period. nVerses Capital LLC raised its holdings in shares of REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares in the last quarter. Diversified Trust Co bought a new stake in shares of REGENXBIO in the 2nd quarter valued at about $121,000. Finally, Arizona State Retirement System raised its holdings in shares of REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.